Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therapix Biosciences Ltd ADR TRPXY

Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the Company's operation); and Pain clinic


OTCPK:TRPXY - Post by User

Post by Fundy13on Nov 21, 2018 12:30pm
147 Views
Post# 29005331

From Analyst

From AnalystI emailed the two analyists who coverTRPX and one just got back to me.  Confimred the info I found that the final number will be $12US per share for TRPX holders.
Also wanted to mention that this is a binding letter of intent, meaning there would be a penalty of some sort payable to the party the freaks the terms if the deal does not go through.  It is not state what the penalty would be, but from my experience they are usually pretty stiff.  FSD probably had to agree to this to have TRPX walk away from other negotiations.

Here is his full email

Hi Ryan,
 
I know it’s confusing.  On page 18 of the PDF for their 424B2 filing they give info on number of ordinary shares and options (remember NASDAQ shares are ADS’s at a 40:1 ratio so 40 ordinary shares per 1 ADS).  So 3.5m shares as you mentioned and then 20.6m options related to ordinary shares (subtracting out what was exercised or expired from what was issued), which puts the fully diluted number over 4m ADS’s.  So it’s closer to $12 per share.  However, remember while this is a “binding letter of intent”, it is not clear what the penalty is for breaking it and they are yet to conclude a definitive agreement. 
 
DESCRIPTION OF ORDINARY SHARES
As of July 13, 2018, our authorized share capital consisted of 300,000,000 ordinary shares, NIS 0.1 par value per share, of which 139,885,534 shares
were issued and outstanding as of such date. All of our outstanding ordinary shares have been validly issued, are fully paid and non-assessable. Our ordinary shares are not redeemable and are not subject to any preemptive right.
 
On January 12, 2014, we effected a reverse split of our share capital, in which every ten ordinary shares were converted to one ordinary share. All
descriptions of our share capital in this prospectus reflect such reverse split.
In the last three years, we have issued an aggregate of approximately 121.5 million ordinary shares in several private placements, options exercises
and public offerings for aggregate net proceeds of NIS 60.5 million (approximately $16.4 million).
 
In addition to ordinary shares, in the last three years, we have issued warrants to purchase an aggregate of 37,867,223 ordinary shares with exercise prices ranging from NIS 0.50 (approximately $0.12) to NIS 1.90 (approximately $0.55) per share, out of which 26,776,256 warrants were exercised and 11,090,967 have expired. In addition, we have granted options to purchase an aggregate of 24,839,278 ordinary shares with exercise prices ranging from NIS 0.50 (approximately $0.13) to NIS 1.061 (approximately $0.28) per share, out of which 41,666 options were exercised and 4,214,779 have expired.
 
I hope this helps!
 
 
Maxim Jacobs, CFA
Managing Partner & Director of Research
 

image: https://c/Users/rohlor9/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg

Edison Logo.jpg
 
295 Madison Avenue
18th FL
New York, NY 10017
 
Tel +1 646 653 7026
DL +1 646 653 7027
Mobile +1 917 439 4729
mjacobs@edisongroup.com 
www.edisongroup.com
Read more at https://www.stockhouse.com/companies/bullboard?symbol=fsddf&postid=29005239#Jr5BOxlezlqbM1i0.99
<< Previous
Bullboard Posts
Next >>